Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 645-652

  Yoshiba, Sayaka ^a   Iwase, Masayasu ^a   Kurihara, Sayaka ^a   Uchida, Makiko ^a   Kurihara, Yuji ^a   Watanabe, Hitoshi ^a   Shintani, Satoru ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cellular FLICE inhibitory protein; Oral squamous cell carcinoma; Proteasome inhibitor; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; FLICE INHIBITORY PROTEIN; PROTEASOME INHIBITOR; RECOMBINANT PROTEIN; SURVIVIN; SYNAPSIN I; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUPEPTINS; MOUTH NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79551578025     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1127     Document Type: Article

References (47)

1. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996. (Pubitemid 26175834)
3. Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4, 2000.
4. Ashkenazi A: Targeting death and decoy receptors of the tumornecrosis factor superfamily. Nat Rev Cancer 2: 420-430, 2002.
5. Younes A and Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21: 3526-3534, 2003.
6. Kondo K, Yamasaki S, Sugie T, et al: Cisplatin-dependent upregulation of death receptor 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer 118: 230-242, 2006.
7. Kim YH and Lee YJ: Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. J Cell Biochem 98: 1284-1295, 2006.
8. Ishii M, Iwai M, Harada Y, et al: Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver. Cancer Lett 245: 134-143, 2007.
9. Dong F, Wang L, Davis JJ, et al: Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 12: 5224-5230, 2006.
10. Mitsiades CS, Treon SP, Mitsiades N, et al: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804, 2001.
11. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM and Repasky EA: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62: 5800-5806, 2002.
12. Uchida M, Iwase M, Takaoka S, et al: Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors. Int J Oncol 30: 1163-1171, 2007.
13. Wang S and El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633, 2003.
14. Takeda K, Stagg J, Yagita H, Okumura K and Smyth MJ: Targeting death-inducing receptors in cancer therapy. Oncogene 26: 3745-3757, 2007.
15. Jarpe MB, Widmann C, Knall C, et al: Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17: 1475-1482, 1998.
16. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
17. Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783, 2004.
18. Huerta-Yepez S, Vega M, Jazirehi A, et al: Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 23: 4993-5003, 2004.
19. Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798, 2008.
20. Gibson SB, Oyer R, Spalding AC, Anderson SM and Johnson GL: Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 20: 205-212, 2000.
21. Itashiki Y, Harada K, Ferdous T and Yoshida H: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res 27: 2365-2375, 2007.
22. Teraishi F, Kagawa S, Watanabe T, et al: ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 579: 4069-4075, 2005.
23. Jesenberger V and Jentsch S: Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3: 112-121, 2002.
24. Zhang HG, Wang J, Yang X, Hsu HC and Mountz JD: Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23: 2009-2015, 2004.
25. Sayers TJ and Murphy WJ: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immune Immunother 55: 76-84, 2006.
26. Iwase M, Watanabe H, Kondo G, Ohashi M and Nagumo M: Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 106: 619-625, 2003.
27. Takaoka S, Iwase M, Uchida M, et al: Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells. Int J Oncol 30: 1469-1476, 2007.
28. Tan ML, Ooi JP, Ismail N, Moad AI and Muhammad TS: Programmed cell death pathways and current antitumor targets. Pharm Res 26: 1547-1560, 2009.
29. Choi K, Ryu SW, Song S, Choi H, Kang SW and Choi C: Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ 17: 833-845, 2010.
30. Leverkus M, Sprick MR, Wachter T, et al: Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23: 777-790, 2003.
31. Tu SP, Sun YW, Cui JT, et al: Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression. Cancer 116: 1252-1263, 2010.
32. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D and Courtois G: The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801-805, 2003.
33. Ryu BK, Lee MG, Chi SG, Kim YW and Park JH: Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194: 15-19, 2001.
34. Rippo MR, Moretti S, Vescovi S, et al: FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 24: 7753-7760, 2004.
35. Sánchez-Pérez T, Ortiz-Ferrón G and López-Rivas A: Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 17: 883-894, 2010.
36. Sayers TJ, Brooks AD, Koh CY, et al: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102: 303-310, 2003.
37. Inoue T, Shiraki K, Fuke H, et al: Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs 17: 261-268, 2006.
38. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB and Gibson SB: The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 11: 1175-1193, 2006.
39. Liu X, Yue P, Chen S, et al: The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 67: 4981-4988, 2007.
40. Yoshida T, Shiraishi T, Nakata S, et al: Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65: 5662-5667, 2005.
41. Shanker A, Brooks AD, Tristan CA, et al: Treating matastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 100: 649-662, 2008.
42. Fukazawa T, FujiwaraT, Uno F, et al: Accelerated degradation of cellular FLIP protein through the ubiquitin-proreasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 20: 5225-5231, 2001.
43. Li W, Zhang X and Olumi AF: MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 67: 2247-2255, 2007.
44. Conticello C, Adamo L, Giuffrida R, et al: Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 92: 1938-1942, 2007.
45. Pukac L, Kanakaraj P, Humphreys R, et al: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Br J Cancer 92: 1430-1441, 2005.
46. Georgakis GV, Li Y, Humphreys R, et al: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130: 501-510, 2005.
47. Marini P, Denzinger S, Schiller D, et al: Combined treatment of colorectal tumors with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145-5154, 2006.